

CBE ID

2467

Title

Adherence to ACEIs/ARBs for Individuals with Diabetes Mellitus

Project

Primary Care and Chronic Illness

Endorsement Status

Endorsement Removed

Is Under Review

No

Previous Endorsement Cycle

Spring 2018

Removal Date

Sun, 03/25/2018 - 20:00

Initial Endorsement

Tue, 09/02/2014 - 13:36

Steward

Centers for Medicare & Medicaid Services

1.0 New or Maintenance

Maintenance

1.1 Measure Structure

Single Measure

1.3 Electronic Clinical Quality Measure (eCQM)

No

1.6 Measure Description

The measure addresses adherence to angiotensin converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs). The measure is reported as the percentage of eligible individuals with diabetes mellitus who had at least two prescriptions for ACEIs/ARBs and who have a Proportion of Days Covered (PDC) of at least 0.8 during the measurement period (12 consecutive months).

1.7 Measure Type

Process

1.8 Level of Analysis

Clinician: Group/Practice, Health Plan, Integrated Delivery System, Population: Regional and State

1.9 Care Setting

Outpatient Services

1.14 Numerator

Individuals in the denominator with at least two prescriptions for ACEIs/ARBs with a PDC of at least 0.8 for ACEIs/ARBs.

1.15 Denominator

Individuals at least 18 years of age as of the beginning of the measurement period with diabetes mellitus and at least two prescriptions for ACEIs/ARBs during the measurement period (12 consecutive months).

1.20 Types of Data Sources

Claims Data, Electronic Health Data, Other

6.1.2 Current or Planned Use(s)

Not in use, Public Reporting, Quality Improvement (Internal to the specific organization), Quality Improvement with Benchmarking (external benchmarking to multiple organizations)

6.1.3 Current Use(s)

Not in use, Public Reporting, Quality Improvement (Internal to the specific organization), Quality Improvement with Benchmarking (external benchmarking to multiple organizations)

Exclusions

We excluded the following individuals from the denominator:

Individuals with polycystic ovaries, gestational diabetes, or steroid-induced diabetes who do not have a face-to-face visit with a diagnosis of diabetes in any setting during the measurement period.

Exclusion 1

Individuals with a diagnosis of polycystic ovaries who do not have a visit with a diagnosis of diabetes in any setting during the measurement period*; and,

Exclusion 2

Individuals with a diagnosis of gestational diabetes or steroid-induced diabetes who do not have a visit with a diagnosis of diabetes mellitus in any setting during the measurement period.

*Adapted from NCQA HEDIS 2013 (2013). Note: HEDIS uses a look-back period of one year prior to the measurement period for both the prescription data and diagnosis.

Measure Disclaimer

This performance measure does not establish a standard of medical care and has not been tested for all potential applications.

Planned Use

Public Reporting, Quality Improvement (Internal to the specific organization), Quality Improvement with Benchmarking (external benchmarking to multiple organizations)

Risk Adjustment

No risk adjustment or risk stratification

Target Population

Dual eligible beneficiaries, Elderly, Populations at Risk

Steward Organization

Centers for Medicare & Medicaid Services

Steward POC email

Helen.Dollar-Maples@cms.hhs.gov